Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)
Study of the Anti-EphA3 Monoclonal Antibody KB004 in Subjects With EphA3-Expressing Hematologic Malignancies
Sponsor: Humanigen, Inc.
Suspended
KaloBios to Wind Down Operations
This PHASE1/PHASE2 trial investigates Myelodysplastic Syndrome (MDS) and Myelofibrosis (MF) and is currently suspended. Humanigen, Inc. leads this study, which shows 7 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Suspended PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Suspended PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Suspended PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Suspended PHASE1_PHASE2
-
Apr 2018 — Jun 2018 [monthly]
Suspended PHASE1_PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Apr 2018 [monthly]
Suspended PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Suspended PHASE1_PHASE2
First recorded
Sep 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Humanigen, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .